Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals.
Abzena works with most of the top 20 biopharmaceutical companies and academic groups all over the world and is focused on enabling the development of better treatments for patients. Abzena’s technologies have enabled many of its customers to progress products (ABZENA inside), through to clinical development.
Abzena was created through the incorporation of Antitope, PacificGMP, PolyTherics and The Chemistry Research Solution (TCRS); all of whom now trade as Abzena. Abzena’s technologies and services are provided across its three sites as follows:
Cambridge, UK (Babraham Research Campus), is the main location of our immunology, protein engineering, bioassays, bioanalytics, cell line development and bioconjugation activities. It is Abzena’s global headquarters; housing our commercial, finance and investor relations teams.
San Diego, CA, USA is home to Abzena’s GMP biopharmaceutical manufacturing plant for Phase I and II clinical trials. Cell banking, process development, batch analysis, QC release and regulatory assistance are all provided at this site for both WAVE and single-use bioreactors.
Abzena’s team in Bristol, PA, USA has a strong background in synthetic organic chemistry and expertise in bioconjugation; providing research chemistry, antibody drug conjugate (ADC) services and manufacture of GMP reagents. The company’s manufacturing capabilities in Bristol is being expanded to enable the manufacture of bioconjugates to GMP standards.
Almac Discovery is a biopharmaceutical company focussed on the discovery and development of novel therapeutics for oncology indications.
Aptus Clinical is a specialist UK- based oncology clinical research organisation which helps life science companies to optimise their clinical development strategies and effectively transform promising molecules into valued medicines.
What makes Aptus Clinical different is our flexibility – our clients benefit from our network of highly experienced and skilled experts from all technical disciplines, but only pay for what they need, when they need it. Our scientists have global expertise in all aspects of drug development so no challenge is too great, and being highly professional, they integrate seamlessly into a client organisation. This gives our clients all the benefits of an in-house clinical department, but at a significantly lower cost. In addition, our well-established relationships with some of the world’s leading experimental cancer centres, access to large patient populations and flexible arrangements to support optimal project delivery are just a few of the benefits to be gained from working with Aptus Clinical.
Whether you need one-off consultancy support, clinical SOP implementation, expert medical or scientific input on a short or long term basis, or a full trial programme, we’d love to hear from you.
Arcinova is a Contract Research and Development Organisation (CRDO), providing the pharmaceutical industry with a comprehensive range of services.
At Arcinova, we are focused on Process, Research, Development, Scale-Up and small scale manufacturing, including bioanalysis, DMPK, regulatory and consulting services, covering drug candidates in Development and launched to the Market.
Chiltern is the leading, global mid-sized contract research organization. We listen to client needs to deliver customized clinical development solutions with a team of more than 4,000 working across 47 countries to provide comprehensive, yet flexible and responsive, services with specialties in Clinical Development, Oncology, Device & Diagnostics, Data, Analytics & Evaluation and Strategic Service Provision.
Clinical Accelerator conducts all phases of clinical trials for pharma, biotech and medtech companies. We have a very simple mission: to accelerate clinical development projects and to reduce their cost appreciably for our clients. We use several strategies to achieve very compact timelines in our clinical studies: - optimization of study design (only necessary outcome measures and end-points, right number of patients, optimal follow-up duration) - selection of effective investigative sites located in our region of operation. All our sites, conducting trials to the highest standards of GCP, have a large patient recruiting capacity and a proven track record of efficient timely recruitment of qualified patients. - accelerated start up (fast regulatory and IRB/EC approval times, streamlined logistics, expedited contracting, fast site activation, USA IND or EU CTA are optional in our region of operation) - effective patient enrolment and retention (dedicated department, proven region-specific patient recruitment strategies) We are specialists in effective and timely patient recruitment, and commit to achieving patient enrolment targets within fixed timelines. We routinely rescue stalled clinical trials. We are able to reduce the cost of our clinical projects significantly due to our: - flat organizational hierarchy, reasonable service rates and very modest internal overhead costs - commitment to agreed fixed budgets (rare need for change orders) - modest investigator grants and low hospital overheads in our region of operation (very large savings can be achieved in many therapeutic areas) - use of as few locations and as few investigative sites as possible without compromising patient recruitment rates (this limits set-up costs and lowers per patient cost) - short study timelines, which lead to reduced management costs - potential risk sharing (optional strategy) The cost of our studies is among the most attractive globally. We commit to our budgets and fix them for our clients.
Clinical Network Services (CNS) Ltd
Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA. CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.
CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team. BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.
With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies. CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle.
Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.
Fusion provides contract services include...
- Antibody Humanization services
- Antibody Engineering Services
- Antibody sequencing Services
- Protein Expression & Purification Services
- Monoclonal Antibody services BLAST & Standard
- cGMP Services
IAG - Image Analysis Group
IA-Group is a strategic partner to bio-pharmacutical companies. We bring extensive therapeutic knowledge and regulatory expertise in strategic use of clinical imaging to enhance understanding of the mode of action, to increase the efficiency of clinical decisions and to accelerate drug development.
IA’s operations team leverage our global footprint and the next-generation cloud based proprietry platform Dynamika to de-risk trial execution and to ensure data quality and integrity. Our venture arm pioneer unique targeted investment and risk-sharing models to enable our clients to reach the next value inflection point faster. We fuse decades of theraputic insight and agile culture to meet today's speed and high standard of therapeutic innovation.
Precision for Medicine, Oncology & Rare Disease
Precision for Medicine, Oncology and Rare Disease is proud to offer the first comprehensive, fully integrated clinical development solution. We are devoted exclusively to oncology and rare disease, and our teams are passionate about improving the lives of these patients. By combining the progressive science of biomarkers and analytics with our excellence in complex clinical trial execution, we help innovators to invest wisely, discover value sooner and optimize the returns from research.
Contact Precision for Medicine, Oncology and Rare Disease via their website